Literature DB >> 16597633

SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships.

Virginia C Gould1, Matthew B Avison.   

Abstract

OBJECTIVES: To test whether smeDEF overexpression leads to a predictable multi-drug resistance phenotype in Stenotrophomonas maltophilia and to measure the frequency with which smeDEF overexpression occurs in clinical isolates and in spontaneous drug-resistant mutants.
METHODS: Overexpression of smeDEF was induced in clinical isolates by the introduction of chromosomal mutations in smeT using a gene-replacement approach. Spontaneous drug-resistant mutants were selected using greater than MIC concentrations of various antimicrobial agents. Levels of smeE and smeF mRNAs were quantified using RT-PCR; MICs were determined using Etest.
RESULTS: Of 20 spontaneous S. maltophilia drug-resistant mutants tested, four overexpressed smeDEF, but only two carried mutations within smeT. Of 30 clinical isolates tested, 6 significantly overexpressed smeDEF. One of these had an IS1246-like element embedded within the putative SmeT binding site in the smeDEF promoter. All smeDEF overexpressing derivatives of an isolate had the same resistance profile; derivatives that did not overexpress smeDEF did not share this resistance profile. However, no consistent phenotype could be associated with smeDEF overexpression in S. maltophilia isolates per se.
CONCLUSIONS: SmeT is not the only gene product that affects smeDEF expression. IS element insertion is a viable mechanism by which smeDEF expression can be derepressed. There is evidence for a background-specific, predictable effect on resistance profile when smeDEF is overexpressed, but the variability of backgrounds encountered means no general SmeDEF-mediated phenotype can be defined. There is strong evidence for the existence of as yet unidentified multi-drug efflux pumps in this species.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597633     DOI: 10.1093/jac/dkl106

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

2.  Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 3.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

4.  Two different rpf clusters distributed among a population of Stenotrophomonas maltophilia clinical strains display differential diffusible signal factor production and virulence regulation.

Authors:  Pol Huedo; Daniel Yero; Sònia Martínez-Servat; Iratxe Estibariz; Raquel Planell; Paula Martínez; Angels Ruyra; Nerea Roher; Ignasi Roca; Jordi Vila; Xavier Daura; Isidre Gibert
Journal:  J Bacteriol       Date:  2014-04-25       Impact factor: 3.490

Review 5.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

6.  Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.

Authors:  Virginia C Gould; Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

7.  Novel Mechanisms of Efflux-Mediated Levofloxacin Resistance and Reduced Amikacin Susceptibility in Stenotrophomonas maltophilia.

Authors:  Punyawee Dulyayangkul; Karina Calvopiña; Kate J Heesom; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

8.  Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.

Authors:  Karina Calvopiña; Klaus-Daniel Umland; Anna M Rydzik; Philip Hinchliffe; Jürgen Brem; James Spencer; Christopher J Schofield; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  Stenotrophomonas maltophilia encodes a type II protein secretion system that promotes detrimental effects on lung epithelial cells.

Authors:  Sara M Karaba; Richard C White; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

10.  Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations.

Authors:  María Carmen Turrientes; María Rosario Baquero; María Blanca Sánchez; Sylvia Valdezate; Esther Escudero; Gabrielle Berg; Rafael Cantón; Fernando Baquero; Juan Carlos Galán; José Luis Martínez
Journal:  Appl Environ Microbiol       Date:  2010-01-22       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.